A PSA-activated protoxin (PRX302) administered transperineally to men with BPH is well tolerated and induces reduction in prostate volume and symptomatic relief

Abi-Habib, Ralph J.; Pommerville, Peter J.; Steinhoff, Gary

A PSA-activated protoxin (PRX302) administered transperineally to men with BPH is well tolerated and induces reduction in prostate volume and symptomatic relief

Abi-Habib, Ralph J.; Pommerville, Peter J.; Steinhoff, Gary

URL: https://www-clinicalkey-com.ezproxy.lau.edu.lb:2443/service/content/pdf/watermarked/1-s2.0-S0022534709619686.pdf?locale=en_US

Date: 2018-06-13

Terms of Use: This item is made available under the terms and conditions applicable to " Article ", as set forth at: http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php

Citation:

Pommerville, P. J., Steinhoff, G., Denmeade, S., Merchant, R., Buckley, T., & Abi-Habib, R. J. (2009). A PSA-ACTIVATED PROTOXIN (PRX302) ADMINISTERED TRANSPERINEALLY TO MEN WITH BPH IS WELL TOLERATED AND INDUCES REDUCTION IN PROSTATE VOLUME AND SYMPTOMATIC RELIEF. The Journal of Urology, 181(4), 704.